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Does Incident Solar Ultraviolet Radiation Lower Blood Pressure?
Richard B. Weller, MD; Yuedong Wang, PhD; Jingyi He, PhD; Franklin W. Maddux, MD; Len Usvyat, PhD; Hanjie Zhang, MA;
Martin Feelisch, PhD;* Peter Kotanko, MD*
Background-—Hypertension remains a leading global cause for premature death and disease. Most treatment guidelines
emphasize the importance of risk factors, but not all are known, modifiable, or easily avoided. Population blood pressure correlates
with latitude and is lower in summer than winter. Seasonal variations in sunlight exposure account for these differences, with
temperature believed to be the main contributor. Recent research indicates that UV light enhances nitric oxide availability by
mobilizing storage forms in the skin, suggesting incident solar UV radiation may lower blood pressure. We tested this hypothesis by
exploring the association between environmental UV exposure and systolic blood pressure (SBP) in a large cohort of chronic
hemodialysis patients in whom SBP is determined regularly.
Methods and Results-—We studied 342 457 patients (36% black, 64% white) at 2178 US dialysis centers over 3 years. Incident
UV radiation and temperature data for each clinic location were retrieved from the National Oceanic and Atmospheric
Administration database. Linear mixed effects models with adjustment for ambient temperature, sex/age, body mass index, serum
Na+/K+ and other covariates were fitted to each location and combined estimates of associations calculated using the
DerSimonian and Laird procedure. Pre-dialysis SBP varied by season and was 4 mm Hg higher in black patients. Temperature,
UVA and UVB were all linearly and inversely associated with SBP. This relationship remained statistically significant after correcting
for temperature.
Conclusions-—In hemodialysis patients, in addition to environmental temperature, incident solar UV radiation is associated with
lower SBP. This raises the possibility that insufficient sunlight is a new risk factor for hypertension, perhaps even in the general
population. ( J Am Heart Assoc. 2020;9:e013837. DOI: 10.1161/JAHA.119.013837.)
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H ypertension is a leading global cause for prematuredisease and death, affecting >1 billion people world-
wide. Its pathophysiology involves complex interactions of
multiple genetic, behavioral/lifestyle-related and environmen-
tal risk factors and social stressors with the endocrine,
metabolic, autonomic nervous and cardiovascular systems.
Without overt symptoms, hypertension can remain unrecog-
nized and escape detection1 for considerable time during
which the raised blood pressure (BP) inflicts end-organ
damage. Multiple pharmacological and interventional treat-
ment options exist but not all are well tolerated, in particular
by older patients. There is convincing evidence from a large
body of epidemiological data and clinical trials that BP
lowering is associated with reduced cardiovascular risk and
mortality, especially from myocardial infarction and stroke.2,3
The 2017 ACC/AHA Guidelines4 for the Prevention,
Detection, Evaluation and Management of Hypertension
redefined what constitutes a “normal BP” to <120 mm Hg
systolic and <80 mm Hg diastolic, irrespective of age,
sensibly focusing on systolic blood pressure (SBP) in older
patients.5 While these aggressive diagnostic thresholds and
treatment targets have not been adopted by the 2018 ESC/
ESH Guidelines for the Management of Arterial Hypertension6
their impact is nevertheless likely to extend well beyond the
practice of medicine in the United States and evoked lively
discussions.7–14 In agreement with the “call to action” by the
2016 Lancet Commission on Hypertension,2 most guidelines
emphasize non-pharmacological intervention options before
From the Center for Inflammation Research, University of Edinburgh, United
Kingdom (R.B.W.); Department of Statistics & Applied Probability, University of
California - Santa Barbara, Santa Barbara, CA (Y.W., J.H.); Integrated Care
Analytics, Fresenius Medical Care North America, Waltham, MA (F.W.M., L.U.);
Renal Research Institute, New York, NY (H.Z., P.K.); Clinical & Experimental
Sciences, Faculty of Medicine, and Institute for Life Sciences, Southampton
General Hospital, University of Southampton, United Kingdom (M.F.).
Accompanying Data S1, Tables S1 through S13, and Figures S1 through S5
are available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.
119.013837
*Prof. Feelisch and Dr Kotanko contributed equally to this work.
Correspondence to: Richard B. Weller, MD, Center for Inflammation
Research, University of Edinburgh, 47 Little France, Crescent, Edinburgh
EH16 4TJ, United Kingdom. E-mail: r.weller@ed.ac.uk
Received September 5, 2019; accepted December 12, 2019.
ª 2020 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is properly cited.
DOI: 10.1161/JAHA.119.013837 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on March 6, 2020
initiation of/in combination with antihypertensive drug treat-
ment. Risk factors such as poor diet, salt/alcohol intake,
smoking, obesity, and physical inactivity are the focus of
current interventions. However, long-term compliance is a
concern, not all factors (eg, aging, (epi)genetics) are modifi-
able, and environmental risks such as transportation noise
and air pollution15 are not easily avoided in urban areas.
Comparatively little effort has been spent on identifying
beneficial environmental factors, but geographical and sea-
sonal variations in BP may provide important clues.
Seasonal BP variation was first reported in ischemic heart
disease patients in the early 1960s.16 BP and cardiovascular
mortality in temperate countries of the Northern hemisphere
show a marked seasonal trend, being higher in winter than
summer.17 Both daylight length and ambient temperature
correlate inversely with BP.18 Population BP also correlates
inversely with latitude.19 Chronic hemodialysis patients are no
exception to these associations20 but have a markedly
increased cardiovascular mortality risk due to the extra
burden of fluid overload, chronic inflammation and oxidative
stress.21,22 Thus adequate BP control is essential to improve
their outcomes.20 Identifying an easily modifiable environ-
mental modulator of BP would suggest lifestyle interventions
that could improve cardiovascular health in this vulnerable
patient cohort.
While epidemiological data suggest a role for sunlight in
lowering BP, its mechanism of action is uncertain. The warmth
of sunshine may contribute to but cannot account entirely for
seasonal BP variation when measured in a temperature-
controlled doctor’s office or at home. In 2010, we proposed
that solar ultraviolet (UV) radiation may contribute to
cardiovascular health by releasing nitric oxide (NO) from
storage forms in the skin23 and later demonstrated that short
UV exposures acutely lower BP24 in healthy human volun-
teers. The relatively modest number of individuals investi-
gated in earlier epidemiological studies prevented UV
radiation from being identified as a potential BP-modulating
variable, and limited information is available as to whether
effects differ between different ethnicities. We therefore
sought to test the hypothesis that incident solar radiation
modulates BP in a very large and diverse cohort of chronic
hemodialysis patients. We chose the hemodialysis setting
because in these patients BP is routinely and frequently
measured in a procedurally standardized fashion in vast
numbers, across multiple environmentally different locations
within a single healthcare set-up. We are unaware of the
availability of other such temporally and geographically
extensive blood pressure data sets. Although our findings
are most directly applicable to patients on hemodialysis, we
believe that they raise important questions for environmental
management of population BP more generally.
Methods
Participants and Blood Pressure Data
This observational study included 342 457 patients undergo-
ing chronic hemodialysis in 2178 US Fresenius Medical Care
facilities (see Figure S1 for location of dialysis centers and
distribution of patient numbers) between January 2011 and
December 2013. It was reviewed by the Western Institutional
Review Board’s Affairs Department and as it was deemed to
meet the conditions for exemption under 45 CFR 46.101 (b)
(4) the requirement for consent was waived. Because of the
sensitive nature of the data collected for this study, requests
to access the data set from qualified researchers trained in
human subject confidentiality protocols may be sent to the
Renal Research Institute at 315 East 62nd Street, 4th Floor |
New York, NY 10065. Patients visited dialysis facilities on
average 3 times per week and had their BP measured before
each treatment by a standard protocol while sitting, using an
automated device with an appropriate-size pressure cuff
around the upper arm positioned at heart level. On average at
least 10 to 15 minutes lapsed between arrival at the facility
and BP measurements. We used monthly averages of pre-
dialysis systolic blood pressures (SBP) as the response
variable. These monthly averages were based on an average
of 11.3 measurements. We analyzed systolic rather than
diastolic BP as in dialysis patients the former is associated
with patient outcomes.25 Demographic variables such as race,
Clinical Perspective
What Is New?
• In a large North American cohort of chronic hemodialysis
patients, incident solar ultraviolet radiation was found to be
associated with lower systolic blood pressure, even after
adjustment for environmental temperature, showing that
human exposure to ultraviolet light contributes to blood
pressure regulation and accounts for seasonal and geo-
graphical variation.
What Are the Clinical Implications?
• While this is an observational study, our findings are
consistent with data showing reduced blood pressure and
lower rates of cardiovascular disease in populations with
higher sun exposure, and suggest that Vitamin D indepen-
dent benefits of sunlight should be considered when
assessing risk benefit ratios.
• Sunlight exposure appears to lower blood pressure; insuf-
ficient exposure to natural ultraviolet radiation and/or
active avoidance of sunlight may be new risk factors for
hypertension.
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sex, age, catheter use, and monthly averages of body mass
index, interdialytic weight gain, albumin, erythropoietin use,
hemoglobin, serum sodium and potassium were used as
covariates. A diagnosis of hypertension in the patient record
was also used as a co-variate as this corresponds to anti-
hypertensive medication use.
Collection of UV and Temperature Data
Our goal was to investigate associations between SBP and UV,
with adjustment for clinical covariates and ambient tempera-
ture. Since it was not feasible to determine personal exposures
to UV radiation and temperature, we approximated these
exposures using environmental data retrieved from public
databases at matched locations. The 2178 facilities were
divided into 1530 geographical locations according to their zip
codes. For each location, we first computed hourly spectral
irradiances (W/m2) at each wavelength from 280 to 400 nm
using the tropospheric UV and visible radiation model from the
US National Center for Atmospheric Research (NCAR) (http://
cprm.acom.ucar.edu/Models/TUV/Interactive_TUV/), corre-
sponding to >25 million hourly records for UVA and UVB for
the entire observation period. We then computed hourly UVA
and UVB as the summations of spectral irradiances over
wavelength ranges 321 to 400 and 280 to 320 nm, respec-
tively. Lastly, we computed summations of hourly UVA and UVB
over each day to approximate the total exposure, and averages
of daily UVA and UVB to calculate monthly averages. See
Figures S2 and S3 for seasonal averages of outdoor exposure
to UVA/UVB radiation by location.
Daily average temperatures (°C) for all locations were
derived from the US National Oceanic and Atmospheric
Administration web site (http://www.ncdc.noaa.gov/cdo-
web/search). See Figure S4 for average outdoor tempera-
tures by location. For locations lacking temperature stations
with matching latitude/longitude we approximated tempera-
tures from those within the shortest great circle distance
using spherical law of cosines.
Statistical Analyses
Our aim was to investigate the relationship between pre-
dialysis SBP and UVA/UVB exposure. Since we had repeated
measurements of SBP from each patient, associations may
vary among different locations, and the data set was too large
to fit a single spatial-temporal model, we adopted a 2-stage
procedure. (1) We first fitted a linear mixed-effects model for
repeated measurements from all patients at each location
with an unstructured covariance matrix for random intercept
and slope. This model takes into account between-patient
variability and the within-patient correlation of SBP measure-
ments across time points. This approach produced estimates
of population intercept and slope at each location. (2) We then
computed a combined estimate of association based on
estimated population slopes from all locations using the
DerSimonian and Laird procedure for random effects meta-
analysis,26 including CIs and P values. To assess the
assumption of the second stage analysis, we fitted thin-plate
splines to explore spatial patterns. We considered 3 analyses
for associations between SBP and UVA/UVB: Model 1: no
adjustment for covariates; Model 2: adjustments for sex, age,
hypertension, use of central venous catheter as vascular
access, body mass index, interdialytic weight gain, albumin,
erythropoietin dose, hemoglobin, serum sodium, and potas-
sium, and a linear trend over calendar time; Model 3:
adjustment for ambient temperature in addition to all Model 2
covariates. As expected, incident UV radiation and environ-
mental temperature were closely associated. To detect
potential problems with collinearity, we computed the
variance inflation factor of temperature when UVA or UVB
was in the model. The variance inflation factors equaled 2.82
for the combination of temperature and UVA and 2.85 for
temperature and UVB; since both were smaller than the cutoff
value of 5, we deemed that collinearity was not a problem.
Separate analyses were performed for black and white
patients. We used the complete case analysis since we have
a large data set, from which there was only a small
percentage of missing values (Table S1). Other than age,
most missing values were caused by missing dialysis treat-
ments. This was typically because of patient hospitalization.
We adopted the partly conditional approach where the
analysis is conditional on being alive.27 To address concerns
about correlation among estimated slopes we fitted a thin-
plate spline model to slope estimates to investigate spatial
pattern. Based on these fits we concluded that correlation of
the slope estimates across sites was negligible relative to the
amount of noise in them. As a sensitivity analysis, we divided
all patients into 4 groups according to longitude and 4 groups
according to latitude. Estimates based on longitude strata are
listed, from west to east, in Tables S2 through S4 for Models
1 to 3, and estimates based on latitude strata, from south to
north, are listed in Tables S5 through S7 for Models 1 to 3.
The combined results in these tables did not change the
pattern of results. All statistical analyses were performed
using R version 3.2.2 (Foundation for Statistical Computing,
Vienna, Austria). A complete description of the statistical
methods is provided in Data S1 with estimated measures of
covariates for each of the models (Tables S8 through S11).
Results
Our cohort included a large fraction of US hemodialysis
patients undergoing in-center hemodialysis between January
2011 and December 2013. Over a third of patients were
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black, consistent with the high incidence of end-stage renal
disease in this community, and the average follow-up time
was 12 months (Table 1). Dialysate sodium levels dropped
by 0.25 mEq/L (95% CI 0.24–0.26) and erythropoietin dose/
treatment by 34.4%, suggestive of improved standards of care
over the observation period.
By computing monthly averages from a total of
45 784 963 individual BP measurements recorded over
36 months we observed clear seasonal variation in SBP
(Figure 1A). Independent of this, there was a gradual fall of
1 mm Hg in SBP over the 3-year period (Figure S5). SBP
was 4 mm Hg higher in black than white dialysis patients.
Mean annual SBP was highest in the south-eastern states
except Florida, mapping onto what is known as the “stroke
belt” (Figure 1B). We next computed monthly averages of
outdoor temperature and solar radiation (in the form of UV
light) at each of the dialysis facilities using high-fidelity daily
and hourly records retrieved from public databases. Temper-
ature, UVA and UVB all showed the expected seasonal
variation and geographical distribution (Figure 2 and Figures
S2 through S4). All 3 variables were linearly and inversely
associated with measured SBP (Figure 3). Means (and SD) of
temperature, UVA and UVB were 16.0 (9.02) °C, 320.9
(118.0) W/m2, and 14.7 (7.13) W/m2, respectively. Although
Table 1. Patient Demographics, Clinical/Laboratory Parameters and Dialysis Treatment Data With Means and Standard Deviations
Variable
All (N=342 457)
(100%)
Black (n=123 908)
(36.2%)
White (n=218 549)
(63.8%)
Mean SD Mean SD Mean SD
Average follow-up time, mo 12.51 12.16 14.05 12.85 11.64 11.67
Demographics
Men, % 57 54 59
Age, y 59.46 15.55 55.30 15.13 61.84 15.28
Body mass index, kg/m2 29.17 7.97 29.39 8.25 29.04 7.80
Existing hypertension, % 66.96 70.83 64.78
Clinical data
Pre-dialysis SBP, mm Hg 146.84 20.72 149.87 20.36 145.13 20.72
Post-dialysis SBP, mm Hg 137.79 18.79 139.97 18.80 136.55 18.66
Pre-dialysis DBP, mm Hg 76.83 12.53 80.62 12.45 74.68 12.05
Post-dialysis DBP, mm Hg 72.46 10.89 75.37 10.95 70.81 10.50
Pre-dialysis weight, kg 84.73 23.56 86.49 24.32 83.73 23.06
Post-dialysis weight, kg 82.36 23.06 84.03 23.81 81.41 22.57
Pre-dialysis body temperature, °C 36.36 0.29 36.38 0.28 36.34 0.29
Post-dialysis body temperature, °C 36.43 0.27 36.45 0.27 36.42 0.28
Laboratory data
Serum sodium, mEq/L 138.38 2.84 138.93 2.61 138.05 2.92
Serum potassium, mEq/L 4.71 0.54 4.64 0.51 4.74 0.55
Hemoglobin, g/dL 10.80 0.96 10.80 0.96 10.81 0.96
Albumin, g/dL 3.75 0.45 3.80 0.43 3.73 0.45
Dialysis treatment data
Central venous catheter as vascular access, % 24.65 20.85 26.80
Treatment time, min 219.80 29.02 222.28 29.50 218.38 28.65
Ultrafiltration rate, mL/h per kg 8.43 3.40 8.51 3.27 8.39 3.48
Equilibrated, Kt/V 1.50 0.28 1.45 0.23 1.52 0.30
Interdialytic weight gain, kg 2.48 1.14 2.57 1.11 2.43 1.16
Erythropoietin dose (U/dialysis) 4178 4716 4419 4872 4042 4619
Differences between black and white patients are significant for all variables (all P<0.05). Monthly data from January 2011 to December 2013 were collected from each of 342 457
patients who underwent dialysis in 2177 Fresenius Medical Care North America facilities. These 2177 facilities correspond to 1925 zip codes and 1530 latitude and longitude location
pairs, and 44 111 patients died during this period. DBP indicates diastolic blood pressure; SBP, systolic blood pressure
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UV and temperature were closely associated (correlation
coefficients between UVA/UVB and temperature: 0.80/0.81),
collinearity was deemed not to be a problem.
We next fitted 3 separate models to adjust for possible
confounders. The SBP fall with increasing incident UV
exposure was seen in Model 1 (unadjusted data) and Model
2 (with adjustment for covariates). Correcting for temperature
(in Model 3) did not alter the statistically significant inverse
relationship between UV and SBP, albeit less strongly than
before (Table 2). The fall in SBP for a given rise in energy was
greater for UVB than UVA, and larger in whites than blacks.
Secondary analyses with standardized UV and temperature
further corroborated these results (Tables S12 and S13).
When temperature was divided into 4 strata, the effects of UV
appeared to be larger when it was warmer, at least in whites,
ie, the same UV radiation energy was associated with greater
BP reduction at elevated temperatures (Table S13). Taken
together, our analyses indicate that pre-dialysis SBP is
affected by solar UV radiation, even after adjustment for the
prevailing outdoor temperature.
Discussion
We here demonstrate an inverse correlation between pre-
dialysis SBP and incident UV radiation in a large and diverse
cohort of US hemodialysis patients. Seasonal variation in blood
pressure has previously been demonstrated in hypertensive
populations17 and in patients on hemodialysis.28 Until now,
however, these variations were attributed to differences in
temperature alone. The size of our cohort and the mapping of
detailed environmental data onto geographical locations
allowed us to differentiate between different seasonally varying
environmental factors affecting BP. The major finding of our
study is that UV radiation intensity is inversely associated with
SBP and that this association is independent of (albeit possibly
modified by) the ambient temperature. Interestingly, despite
dominating fluid-dependent effects on BP in hemodialysis
patients, an association between incident solar UV radiation
and pre-dialysis SBP could be discerned. This may account for
the recent observation that mortality is lower in dialysis
patients on sunnier days.29 If these observations were
confirmed in non-dialysis subjects, this could be of consider-
able public health significance as lower population BP directly
translates into reduced renal, cerebrovascular and cardiovas-
cular disease and lower mortality. We hope that these results
will invigorate the search for other potentially beneficial
environmental factors contributing to health and wellbeing.
Many cellular and bodily functions are subject to diurnal
and seasonal change.30 Seasonal variation of BP is a complex
phenomenon31,32 that has been attributed mainly to varia-
tions in temperature or humidity,21,28 although these variables
are compounded by measurement errors and show poor
agreement between indoor/outdoor conditions during the
heating season.33 The geographical diversity and large
number of dialysis centers at which we have collected data
has enabled us to clearly discriminate between temperature
and UV exposure. Consistent with previous reports,17,21,28 we
find that temperature does indeed correlate with BP, but
independently of this, so does UV. Our measures relate to
incident UV outdoors. There is some evidence that environ-
mental UV correlates with personal UV exposure,34 but in our
cohort of patients with chronic illness we expect that the
variations of environmental radiation recorded are a signifi-
cant overestimate of the personal exposure experienced.
Window glass absorbs almost all of the UVB, letting only
longer wavelength UVA, visible and infrared light penetrate.
Nevertheless, we suspect that most UV radiation is received
during periods of time spent outside and the actual radiation
received will only be a small proportion of that incident at
each study site. Moreover, recent studies have shown that
hemodialysis patients in New York, NY, walk significantly
more than those in Baton Rouge, LA.35 If such differences in
physical activity levels were consistent across the northern/
southern state divide, this would be a further factor that could
reduce BP in the less sunny north and confound estimated
UV-induced BP reduction. In this context the strong and
consistent inverse association between environmental UV and
SBP we here identified is striking, particularly as dialysis
patients are often frail and spend relatively little time outside.
Many factors other than UV radiation affect BP. A great
number of patients included in our study will have received
antihypertensive medication, and the effect of the dialysis
procedure on SBP is well known. However, one would not
expect the former to change by season nor the latter to vary
by geographical location. We observed a gradual fall of
1 mm Hg in recorded pre-dialysis SBP over the 3-year study
period. While it is difficult to attribute this declining SBP trend
to a specific intervention, erythropoietin use declined, and
dialysis providers strive to improve fluid management by
reducing dialysate sodium levels. In small studies these
interventions resulted in SBP reductions, in particular in
hypertensive patients.36,37 We observed that mean SBP
throughout the year was higher in southeastern states,
consistent with the observation that hypertension is more
prevalent in this part of the United States 38 (Figure 1B),
despite the relatively high incident sunlight there. This area is
known as the “stroke belt” of America and has had the
highest incidence of cerebrovascular and cardiovascular39
deaths in the country since the middle of the 20th century,
although the reason(s) for the underlying hypertension remain
(s) uncertain. Whatever their nature, these factors must
be strong enough to outweigh the hypotensive effects of
sunshine.
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If exposure to sunlight does indeed lower BP, a biologically
plausible mechanism must be invoked. The intensity and
spectral balance of solar radiation varies geographically and is
affected most by latitude, altitude, and season. UVA (320–
400 nm), the predominant form of UV reaching the earth’s
surface, will partly pass through window glass and penetrate
as deep as the dermis in skin. Although not absorbed by DNA
(and thus not directly mutagenic), it is absorbed by other
photosensitizers and consequently generates free radicals,
producing oxidative stress. UVB (280–320 nm) is responsible
for the photochemical synthesis of previtamin D3 from 7-
dehydrocholesterol, but is also a direct DNA mutagen. It
makes up 5% of incident UV radiation, and is around 2
orders of magnitude more erythemogenic than UVA. Shorter
wavelength UVB penetrates less well through the atmosphere,
so is reduced more than UVA at low altitude and as the sun’s
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Figure 1. Seasonal, racial and geographical variation in blood pressure. A, Dots are monthly averages, lines are smoothing spline estimates, and
shaded areas are 95% CI. Systolic blood pressure shows seasonal variation and is consistently higher in black than white patients. B through F, States
with study centers and race-specific SBP averages per state in winter and summer across the United States are shown. States with insufficient data
(<10 patients or <2 months of observations) are shown in white. Mean annual SBP is highest in the “stroke belt” states (B). SBP is higher in winter
(C and D) than summer (E and F) in all states. SBP is higher in black (C and E) than white (D and F) patients. SBP indicates systolic blood pressure.
DOI: 10.1161/JAHA.119.013837 Journal of the American Heart Association 6
Does Sunlight Lower Blood Pressure? Weller et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 6, 2020
elevation falls in winter at higher latitudes. Individuals with
high measured vitamin D levels have lower BP, but meta-
analyses of vitamin D supplementation studies,40,41 and
Mendelian randomization studies42 both show that vitamin D
has no effect on BP control or cardiovascular mortality.
Vitamin D itself thus cannot account for any postulated BP-
lowering actions of sunlight, although it may be a marker for
sunlight43 or outdoor activity, which is known to reduce BP.
We24 and others44 have described an alternative mecha-
nism by which UV can lower BP, independently of vitamin D.
Human skin contains significant stores of NO-related prod-
ucts.45 These can be mobilized by UV irradiation45 and blue
light.46 UV radiation induces mobilization of NO from these
stores to the circulation, where it dilates resistance vessels24
and lowers BP.24,44 Photorelaxation of arterial smooth muscle
was first shown ex vivo by Furchgott half a century ago47 and
is possibly mediated via the same mechanism. The immediate
photorelaxation peak in mammalian aorta is at 335 nm, with a
post-depletion maximum at around 310 nm.48 In our cohort
we found that a given energy of UVB was more potent than
UVA at lowering BP as signified by the steeper dose-response
curve (Table 2, Figure 3). It would also appear that the same
photic energy is more efficient at elevated outdoor temper-
atures, at least in whites (Table S7), which may indicate that
Figure 2. Outdoor exposure to solar UV light during a typical winter and summer month and seasonal variation of temperature and UV
radiation. A, Exemplary monthly averages of UVA radiation in January and June 2011 by location (see Data S1 for monthly averages by
wavelength band throughout that year). B, Seasonal variation in UVA exposure and temperature (shaded areas represent 95% CI), and annual
averages by location.
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UV radiation and temperature synergize in cleaving NO-
containing storage forms in the skin. This observation
warrants further investigation, and is consistent with a recent
report of outdoor temperature changes having a larger impact
on BP in southern compared with northern US cities.49
Differential absorption of UV radiation by the atmosphere
results in a higher UVB/UVA ratio in summer, most marked at
higher latitudes, which combined with the greater incident
solar energy will account for reduced summer BP.
The duration of action of the BP-lowering effects of UV
exposure is uncertain. Experimentally, a single exposure to UV
lowers blood pressure for <1 hour in health volunteers,24 yet
the population of patients studied here must have had a more
sustained fall in blood pressure as it lasted long enough to be
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Figure 3. Association between environmental factors and systolic blood pressure. Temperature, UVA and UVB irradiation all inversely
correlate with systolic blood pressure. Each dot represents mean nationwide UV for 1 calendar month. Red dots 2011, green dots 2012, blue
dots 2013. Lines are smoothing spline estimates, and shaded areas are 95% CIs.
Table 2. Relationship Between Systolic Blood Pressure and UV Light as Well as Temperature, Stratified by Skin Color and
Wavelength Band
Model UV Spectrum
White Black
SBP Change Per Unit 95% CIs SBP Change Per Unit 95% CIs
1 UVA 0.78 (0.81 to 0.76) 0.64 (0.68 to 0.61)
UVB 13.24 (13.69 to 12.79) 10.77 (11.32 to 10.21)
2 UVA 0.75 (0.78 to 0.72) 0.63 (0.66 to 0.59)
UVB 12.73 (13.22 to 12.23) 10.49 (11.07 to 9.91)
3 UVA 0.32 (0.37 to 0.27) 0.23 (0.29 to 0.16)
Temperature 8.13 (8.99 to 7.27) 7.37 (8.47 to 6.26)
UVB 5.63 (6.48 to 4.78) 4.17 (5.26 to 3.08)
Temperature 7.92 (8.78 to 7.07) 7.04 (8.15 to 5.94)
Units for UV and temperature are 1009mm Hg/(W9m2) and 1009mm Hg/°C, respectively, where a unit of 1.0 represents a change of population blood pressure of 1 mm Hg for a
change of incident UV of 100 W/m2 or a change of temperature of 100°C. Model 1, no adjustment; Model 2, adjusted for clinical covariates and comorbidities; Model 3, model 2 with
additional adjustment for ambient temperature; see Methods for details. Racial differences for the effects of UV radiation on blood pressure were significant in all models. SBP indicates
systolic blood pressure.
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recorded even when not immediately preceded by sun
exposure. One must therefore assume that the SBP records
used in the present analysis do not reflect acute but instead
capture residual UV-induced effects, and that BP lowering by
chronic environmental UV exposure is secondary to a
sustained shift in a more fundamental regulatory circuit
linked to cardiovascular regulation such as eg, systemic and/
or vascular redox status. Human skin is essentially a
“biological detector” for electromagnetic radiation, and even
low doses of UV elicit “photooxidative stress”.50 This is a
universal response of tissues to light that extends to other life
forms including plants and unicellular organisms, but in
humans it has mostly been studied in the context of skin
aging/photodamage, inflammation and carcinogenesis. It is
conceivable that redox changes in the skin trigger systemic
antioxidant responses, but we neither have experimental
evidence for such a mechanism nor are we aware of any
studies that investigated the relationship between skin redox
and cardiovascular regulation.
Irrespective of mechanism, mean SBP was higher and the
age younger in black than white patients, reflecting the well-
documented higher incidence of hypertension and faster
trajectory of renal function decline in blacks than whites.51 BP
in whites showed a steeper response to UV than that in
blacks. This may reflect constitutive skin pigmentation
shielding UV-induced hypotensive effects. Jablonski argues
that constitutive pigmentation predominantly protects against
UVA, while seasonally altering adaptive pigmentation protects
against seasonal variation in UVB.52 Constitutively dark skin
protects against UV-induced DNA damage,53 and both UVA
and UVB transmission to the dermis is blocked more
effectively by black than white skin. The mean transmission
in the black epidermis is typically 7.4% UVB and 17.5% UVA,
but 29.4% and 55.5% respectively, for white epidermis.54
Apart from these considerations the blunted BP response in
blacks may also be because of effects downstream of UV-
induced release and/or production mechanisms. Salt sensi-
tivity is more common in blacks than whites,55 and reduced
NO bioavailability secondary to increased oxidative stress may
contribute to the higher susceptibility to endothelial dysfunc-
tion, stroke, heart failure, peripheral arterial disease, and
disparities in life expectancy in this population.56,57 In
addition, socioeconomic factors and dietary habits contribute
to the racial disparity in hypertension risk.58 While hyperten-
sion development is a multifactorial affair, the different effects
of UV radiation on white and black patients strengthened the
notion of a skin-mediated direct UV effect, internally validating
our main finding.
We suggested earlier that exposure to natural sunlight23
may be beneficial for health and lower BP for reasons other
than temperature. Modern lifestyles/working habits often
translate into spending much time under artificial indoor
lighting conditions, a topic that appears to have lost its
research appeal.59 This is unfortunate as sunlight is important
for more than vitamin D production and the entrainment of
chronobiological processes. Since life on earth developed
under the influence of solar radiation, it is difficult to imagine
that human physiology should be unable to cope with UV
radiation; more likely, modern man is “out of sync” with this
important environmental stressor, which is an important part
of our exposome. We suggest including UV exposure
measures in future cardiovascular epidemiological studies.60
Nowadays, direct sunlight exposure is discouraged for fear of
skin cancer (since UV is also a mutagen, inappropriate
episodic over-exposure must be avoided). The present study
results indicate that normal environmental UV radiation has a
BP-lowering effect in hemodialysis patients. If confirmed to
also hold true in the general population low exposure to or
avoidance of sunlight may be a new and modifiable risk factor
for hypertension. Of relevance, enhanced sunlight exposure
was found to be associated with lower all-cause mortality in a
large female Scandinavian cohort.61 A 20-year follow-up with
competing-risk analysis of the same cohort revealed that
while a habit of active sun exposure translated into an
increased risk of death from cancer the extended life
expectancy of women with sun-seeking behavior was related
to a decrease in cardiovascular disease-related mortality.
Since increased SBP is the major risk factor for CVD mortality
our data may provide a working hypothesis to explain these
associations.62
The present study has strengths and limitations. Its
strengths relate to the large and diverse patient population,
managed according to a standard protocol, by a single large
dialysis provider with measurements recorded by professional
healthcare providers, allied to high-quality National Center for
Atmospheric Research/National Oceanic and Atmospheric
Administration environmental data. Weaknesses include the
lack of personal-level UV exposure measurements, differences
in BP monitoring devices, the absence of data on anti-
hypertensive therapy, BP in-between dialysis visits, socioeco-
nomic status and physical activity level of patients. Our
conscious decision to omit diastolic BP from our analyses
represents another study limitation. We caution that the data
relate to a North-American cohort and may not necessarily be
relevant for other geographical locations and populations of
distinct genetic heritage. We have mitigated the absence of
individual data on anti-hypertensive medication by including
the diagnosis of hypertension as a covariate, as it is a proxy
marker for medication. This would reduce the apparent effect
size of UV. While circulating vitamin D levels have been used
to estimate personal exposure to UV radiation in other studies
this approach would not be suitable in hemodialysis patients
many of whom receive cholecalciferol supplementation to
prevent secondary hyperparathyroidism63 and the data
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showing that Vitamin D has no effect on cardiovascular
outcomes are extensive and robust.64
Seasonal variation in blood pressure has been known for
40 years, but, to our knowledge, for the first time we show
here that this occurs independently of temperature. The
reduction in blood pressure is more marked with a rise in UVB
than UVA, and in whites than black people. Dermatological
concerns about the skin cancer inducing effects of UV
radiation need to be balanced against the observed blood
pressure lowering effects of sunlight, particularly given the
greatly higher burden of disease caused by hypertension.
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Data S1. 
 
Additional Statistical Methods 
 
Our goal was to investigate the relationship between SBP (systolic blood pressures) and 
UVA/UVB. Since repeated measurements of SBP from each patient at different locations 
were available, we considered a mixed effects model for the spatial-temporal data 
yi(s,t) = β1(s) + b1i + (β2(s) + b2i)x(s, t) + εi(s,t),   s=1,…,S;   t=1,…,T,       (1) 
where yi(s,t) is the monthly average of pre-dialysis SBP of patient i in month t who 
underwent dialysis at location s, x(s, t) is the UVA (or UVB) at time t and location s, β1(s)  
and β2(s)  are population intercept and slope at location s, b1i and b2i are random intercept and 
slope for patient i, εi(s,t) is the random error, S=1350 is the total number of locations, and 
T=36 is the total number of months. We assume that the bivariate random vectors (b1i,b2i) are 
independent and identically distributed (iid) Normal with mean zero and an unstructured 
covariance matrix, εi(s,t) are iid Normal with mean zero and a constant variance, and random 
effects and random errors are mutually independent. We allow the population intercept and 
slope to depend on s since the mean SBP with zero UVA/UVB and association between SBP 
and UVA/UVB may depend on location. We may use a spatial model such as thin-plate 
spline for β1(s) and β2(s). However, the data set is too large to fit the spatial-temporal model 
to the whole data. For each fixed location s, model (1) is a simple linear mixed effect model 
which is feasible to fit. Therefore, we adopted a two-stage procedure: 
1) fit a linear mixed effect model for each location s to get estimates 𝛽2̂(s) ‘s; 
2) fit a thin-plate spline model to investigate spatial pattern and compute combined 
estimates of associations between SBP and UVA/UVB. We estimate and make 
inference of the association using a random effect model in meta-analysis. 
Specifically, under the assumption that 𝛽2̂(s) ‘s are independent among different 
locations, we consider a random effect model 
𝛽2̂(s)  = β2 + ξ(s),  s = 1,…,S, 
where β2 represents mean association between SBP and UVA/UVB, and ξ(s) are iid 
Normal with mean zero and variance τ2. Applying the DerSimonian and Laird 
procedure, we get the combined estimate of association  
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𝛽2̂ = (∑𝑤(𝑠)
𝑆
𝑠=1
)
−1
 (∑𝑤(𝑠)
𝑆
𝑠=1
 𝛽2̂(𝑠)), 
where 
𝑤(𝑠) = (?̂?(𝑠) + 𝜏2̂)
−1
, 
 
?̂?(𝑠) is the estimated variance of 𝛽2̂(s),  
𝜏2̂ = max
{
 
 
 
 
 
 
0,
∑
(𝛽2̂(𝑠) − 𝛽2̃)
2
?̂?(𝑠)
− (𝑆 − 1)𝑆𝑠=1
∑
1
?̂?(𝑠)
𝑆
𝑠=1 −
∑
1
𝑉2̂(𝑠)
𝑆
𝑠=1
∑
1
?̂?(𝑠)
𝑆
𝑠=1 }
 
 
 
 
 
 
 
and 
𝛽2̃ = 
∑
𝛽2̂(𝑠)
?̂?(𝑠)
𝑆
𝑠=1
∑
1
?̂?(𝑠)
𝑆
𝑠=1
 
We note that the above two-stage procedure may be regarded as a divide and recombine 
(divide and conquer) procedure for the analysis of big data2. 
Covariates were not considered in model (1). Based on the literature and preliminary 
analyses, we consider the following covariates: race, gender, age, comorbidity of 
hypertension, catheter use, BMI, IDWG, albumin, EPO dosage, hemoglobin, serum sodium 
and potassium. The ¼-power transformation is used for the EPO dosage. We have found that 
there is a downward linear trend of SBP during 2011-2013 (Figure S5). Furthermore, our 
main interest was to investigate if associations between SBP and UVA/UVB still existed after 
adjusting for temperature. Therefore, we considered the following three analyses:  
i. Model 1: fit model (1) using two-stage analysis without adjustment for covariates. 
ii. Model 2: fit model (1) with covariates race, gender, age, comorbidity of hypertension, 
catheter use, BMI, IDWG, albumin, EPO dosage, hemoglobin, serum sodium, 
potassium and a linear trend for calendar time in the first stage, and then combine 
estimated slopes using the DerSimonian and Laird procedure.  
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iii. Model 3: fit model (1) with all covariates as in (ii) and an additional covariate of 
temperature in the first stage, and then combine estimated slopes using the 
DerSimonian and Laird procedure. 
 
We fitted linear mixed effects models using the lme function in the nlme R package with the 
restricted maximum likelihood (REML) method to estimate variance-covariance parameters. 
Rohrscheib et al3 found that the relationship between blood pressure and age has an inverted 
“U”-shape for hemodialysis patients. Therefore, we conducted a sensitivity analysis where a 
quadratic function of age was added to Models 2 and 3. Estimated coefficients are listed in 
Tables S3A and S4A. Relationships between SBP and UVA/UVB are almost identical as 
those in Tables S1A and S2A. Therefore, conclusions remain the same.  We had performed 
diagnostics to evaluate the model assumptions. We had also conducted other sensitivity 
analyses (not presented) and the conclusions remain the same.   
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Figure S5. Seasonal variation in (pre-dialysis) systolic blood pressure superimposed onto linear 
downward trend in African-American and White hemodialysis patients. 
 
 
 
 
 
 
 
Top panels are partial spline fits to monthly averages of SBP. Middle and bottom panels are, 
respectively, the seasonal trend and long-term trend over calendar time based on the partial spline fits. 
Left and right panels correspond to Black and White patients. There is a clear downward linear trend 
over calendar time which is included in Models 2 and 3. We attribute this downward trend to 
improved standards of care over the observation period.   
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Table S1. Percentages of all variables with missing data. 
 
 
 
All 
(N=342,457) 
Black 
(N=123,908)    
(36.2%) 
White 
(N=218,549) 
(63.8%) 
    Variables Missing % Missing % Missing % 
SBP 5.61 5.12 5.94 
Albumin (g/dL) 8.38 7.60 8.91 
Age (years) 0.91 0.75 1.01 
Interdialytic weight gain (kg) 1.61 1.48 1.70 
Serum sodium (mEq/L) 15.89 13.69 17.42 
Body mass index (kg/m2) 7.71 6.35 8.64 
Serum potassium (mEq/L) 7.87 7.31 8.26 
Hemoglobin (g/dL) 4.19 3.85 4.42 
Temperature (°C) 18.05 16.58 19.06 
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Table S2. Relationship between systolic blood pressure and ultraviolet light stratified by race and temperature and 
longitude based on Model 1. 
  
White Black 
Longitude 
UV spectrum SBP change per 
unit UV  95% Confidence intervals 
SBP change per 
unit UV 
95% Confidence 
intervals 
  (-125,-110] 
UVA -1.00 (-1.07 to -0.92) -0.96 (-1.15 to -0.77) 
UVB -16.78 (-17.99 to -15.57) -15.94 (-19.06 to -12.82) 
(-110,-95.8] 
UVA -1.00 (-1.08 to -0.91) -0.91 (-1.09 to -0.73) 
UVB -16.25 (-17.60 to -14.90) -14.70 (-17.59 to -11.81) 
(-95.8,-81.4] 
UVA -0.69 (-0.73 to -0.65) -0.62 (-0.68 to -0.56) 
UVB 
-11.74 (-12.40 to -11.08) -10.31 (-11.22 to -9.38) 
(-81.4,-67] 
UVA -0.72 (-0.76 to -0.68) -0.60 (-0.64 to -0.55) 
UVB 
-12.37 (-13.10 to -11.64) -10.10 (-10.90 to -9.30) 
Combined 
UVA 
       -0.78 (-0.81 to -0.76) -0.64 (-0.68 to -0.61) 
UVB 
-13.24 (-13.69 to -12.79) -10.77 (-11.32 to -10.21) 
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Table S3. Relationship between systolic blood pressure and ultraviolet light stratified by race and longitude based on 
Model 2. 
  
White Black 
Longitude UV spectrum SBP change per 
unit UV  95% Confidence intervals 
SBP change per 
unit UV 
95% Confidence 
intervals 
  (-125,-110] 
UVA -1.05 (-1.13 to -0.97) -1.17 (-1.35 to -0.99) 
UVB -17.63 (-18.97 to -16.29) -19.24 (-22.17 to -16.31) 
(-110,-95.8] 
UVA -1.01 (-1.10 to -0.93) -0.93 (-1.11 to -0.74) 
UVB -16.52 (-17.91 to -15.13) -15.06 (-17.98 to -12.14) 
(-95.8,-81.4] 
UVA -0.65 (-0.70 to -0.60) -0.59 (-0.65 to -0.54) 
UVB 
-10.99 (-11.75 to -10.23) -9.87 (-10.78 to -8.97) 
(-81.4,-67] 
UVA -0.66 (-0.70 to -0.61) -0.56 (-0.61 to -0.51) 
UVB 
-11.27 (-12.04 to -10.50) -9.53 (-10.36 to -8.70) 
Combined 
UVA 
       -0.75 (-0.78 to -0.72) -0.63 (-0.66 to -0.59) 
UVB 
-12.73 (-13.22 to -12.23) -10.49 (-11.07 to -9.91) 
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Table S4. Relationship between systolic blood pressure and ultraviolet light stratified by race  and longitude based on 
Model 3. 
  
White Black 
Longitude UV spectrum SBP change per 
unit UV  95% Confidence intervals 
SBP change per 
unit UV 
95% Confidence 
intervals 
  (-125,-110] 
UVA -0.36 (-0.47 to -0.25) -0.23 (-0.48 to 0.03) 
UVB -6.05 (-7.84 to -4.26) -3.88 (-8.08 to 0.32) 
(-110,-95.8] 
UVA -0.31 (-0.46 to -0.16) -0.29 (-0.64 to 0.07) 
UVB -5.39 (-7.80 to -2.99) -4.89 (-10.52 to 0.74) 
(-95.8,-81.4] 
UVA -0.34 (-0.43 to -0.24) -0.25 (-0.36 to -0.14) 
UVB 
-5.88 (-7.42 to -4.34) -4.52 (-6.33 to -2.71) 
(-81.4,-67] 
UVA -0.29 (-0.29 to -0.38) -0.21 (-0.32 to -0.10) 
UVB 
-5.25 (-6.86 to -3.63) -3.86 (-5.69 to -2.03) 
Combined 
UVA 
       -0.32 (-0.37 to -0.27) -0.23 (-0.29 to -0.16) 
UVB 
-5.63 (-6.48 to -4.78) -4.17 (-5.26 to -3.08) 
D
ow
nloaded from
 http://ahajournals.org by on March 6, 2020
Table S5. Relationship between systolic blood pressure and ultraviolet light stratified by race and latitude based on 
Model 1. 
  
White Black 
Latitude UV spectrum SBP change per 
unit UV  95% Confidence intervals 
SBP change per 
unit UV 
95% Confidence 
intervals 
  (25.1,31.2] 
UVA -1.00 (-1.09 to -0.91) -0.78 (-0.89 to -0.68) 
UVB -15.67 (-17.04 to -14.31) -12.36 (-13.95 to -10.76) 
(31.2,37.3] 
UVA -0.92 (-0.97 to -0.87) -0.71 (-0.76 to -0.65) 
UVB -14.99 (-15.77 to -14.20) -11.57 (-12.46 to -10.67) 
(37.2,43.3] 
UVA -0.69 (-0.73 to -0.65) -0.54 (-0.59 to -0.49) 
UVB 
-11.94 (-12.55 to -11.32) -9.40 (-10.24 to -8.56) 
(43.3,49.4] 
UVA -0.56 (-0.63 to -0.48) -0.66 (-1.30 to -0.02) 
UVB 
-10.09 (-11.45 to -8.73) -11.92 (-22.88 to -0.96) 
Combined 
UVA 
       -0.78 (-0.81 to -0.76) -0.64 (-0.68 to -0.61) 
UVB 
-13.24 (-13.69 to -12.79) -10.77 (-11.32 to -10.21) 
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Table S6. Relationship between systolic blood pressure and ultraviolet light stratified by race and latitude based on 
Model 2. 
  
White Black 
Latitude UV spectrum SBP change per 
unit UV  95% Confidence intervals 
SBP change per 
unit UV 
95% Confidence 
intervals 
(25.1,31.2] 
UVA -1.02 (-1.11 to -0.92) -0.81 (-0.91 to -0.70) 
UVB -15.91 (-17.41 to -14.41) -12.72 (-14.42 to -11.01) 
(31.2,37.3] 
UVA -0.87 (-0.93 to -0.82) -0.70 (-0.76 to -0.64) 
UVB -14.32 (-15.24 to -13.39) -11.53 (-12.51 to -10.55) 
(37.2,43.3] 
UVA -0.64 (-0.68 to -0.60) -0.50 (-0.55 to -0.46) 
UVB 
-11.13 (-11.79 to -10.46) -8.79 (-9.60 to -7.97) 
(43.3,49.4] 
UVA -0.57 (-0.65 to -0.49) -0.46 (-0.95 to 0.04) 
UVB 
-10.31 (-11.75 to -8.87) -8.28 (-17.19 to 0.62) 
Combined 
UVA 
       -0.75 (-0.78 to -0.72) -0.63 (-0.66 to -0.59) 
UVB 
-12.73 (-13.22 to -12.23) -10.49 (-11.07 to -9.91) 
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Table S7. Relationship between systolic blood pressure and ultraviolet light stratified by race and latitude based on 
Model 3. 
  
White Black 
Latitude UV spectrum SBP change per 
unit UV  95% Confidence intervals 
SBP change per 
unit UV 
95% Confidence 
intervals 
  (25.1,31.2] 
UVA -0.39 (-0.578 to -0.20) -0.06 (-0.29 to 0.17) 
UVB -5.95 (-8.79 to -3.10) -0.98 (-4.64 to 2.68) 
(31.2,37.3] 
UVA -0.27 (-0.36 to -0.17) -0.27 (-0.38 to 0.16) 
UVB -4.62 (-6.10 to -3.13) -4.81 (-6,.61 to -3.01) 
(37.2,43.3] 
UVA -0.34 (-0.42 to -0.26) -0.25 (-0.36 to -0.15) 
UVB 
-6.24 (-7.61 to -4.88) -4.81 (-6.60 to -3.03) 
(43.3,49.4] 
UVA -0.34 (-0.49 to -0.18) -0.40 (-0.55 to -1.36) 
UVB 
-6.28 (-8.95 to -3.61) 7.13 (-10.32 to 24.58) 
Combined 
UVA 
       -0.32 (-0.37 to -0.27) -0.23 (-0.29 to -0.16) 
UVB 
-5.63 (-6.48 to -4.78) -4.17 (-5.26 to -3.08) 
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Table S8. Estimated coefficients from Model 2, stratified by UV wavelength band and race.  
 
White Black 
Covariates 
SBP 
change 
per unit 
95% Confidence 
intervals 
SBP 
change 
per unit 
95% Confidence 
intervals 
UVA (W/m2) 
-0.0075 (-0.0078 to -0.0072)  -0.0063 (-0.0066 to -0.0059) 
MALE 
-3.7384 (-3.9844 to -3.4924)  -1.7899 (-2.1163 to -1.4634) 
AGE (years) 
-0.1942 (-0.2028 to -0.1855) -0.0771 (-0.0893 to -0.0648) 
EPO DOSE 
(U/dialysis) 
0.2457 (0.2322 to 0.2592) 0.4317 (0.4121 to 0.4513) 
ALBUMIN (g/dL) 
4.6026 (4.4462 to 4.7591) 4.2375 (4.0367 to 4.4383) 
INTERDIALYTIC 
WEIGHT GAIN (kg) 
-0.8292 (-0.8938 to -0.7646) -0.8260 (-0.9129 to -0.7391) 
SERUM SODIUM 
(mEq/L) 
0.1774 (0.1663 to 0.1885)  0.2222 (0.2081 to 0.2364) 
BMI (kg/m2) 
0.2636 (0.2430 to 0.2843) 0.3004 (0.2729 to 0.3279) 
SERUM POTASSIUM 
(mEq/L) 
0.3972 (0.3403 to 0.4540) 0.2689 (0.1943 to 0.3435) 
HYPERTENSION 
5.3344 (5.0689 to 5.5999) 3.8018 (3.3122 to 4.2913) 
HGB (g/dL) 
1.1376 (1.0960 to 1.1792) 0.5007 (0.4517 to 0.5498) 
CATHETER AS 
VASCULAR ACCESS 
0.4708 (0.2910 to 0.6505) 0.6863 (0.4501 to 0.9225) 
TIME (months) 
-0.0553 (-0.0632 to -0.0474) -0.0759 (-0.0857 to -0.0662) 
UVB (W/m2) 
-0.1273 (-0.1322 to -0.1223) -0.1049 (-0.1107 to -0.0991) 
MALE 
-3.7430 (-3.9894 to -3.4965) -1.7873 (-2.1167 to -1.4579) 
AGE (years) 
-0.1941 (-0.2027 to -0.1855) -0.0767 (-0.0892 to -0.0643) 
EPO DOSE 
(U/dialysis) 
0.2459 (0.2324 to 0.2593) 0.4317 (0.4121 to 0.4513) 
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ALBUMIN (g/dL) 
4.6017 (4.4453 to 4.7582) 4.2356 (4.0347 to 4.4365) 
INTERDIALYTIC 
WEIGHT GAIN (kg) 
-0.8310 (-0.8956 to -0.7663) -0.8268 (-0.9138 to -0.7398) 
SERUM SODIUM 
(mEq/L) 
0.1770  (0.1659 to 0.1881) 0.2217 (0.2075 to 0.2358) 
BMI (kg/m2) 
0.2635 (0.2428 to 0.2843) 0.3008 (0.2733 to 0.3284) 
SERUM POTASSIUM 
(mEq/L) 
0.3981 (0.3412 to 0.4549)  0.2692 (0.1945 to 0.3439) 
HYPERTENSION 
5.3330 (5.0673 to 5.5988) 3.8205 (3.3253 to 4.3157) 
HGB (g/dL) 
1.1389 (1.0972 to 1.1805) 0.5011 (0.4520 to 0.5502) 
CATHETER AS 
VASCULAR ACCESS 
0.4717 (0.2919 to 0.6515)  0.6858 (0.4496 to 0.9220) 
TIME (months) 
-0.0548 (-0.0627 to -0.0469) -0.0757 (-0.0854 to -0.0659) 
 
 
The dose of erythropoietin (EPO DOSE) was transformed by raising it to the power of ¼. 
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Table S9. Estimated coefficients from Model 3, stratified by wavelength band and race.  
 
White Black 
Covariates 
SBP 
change 
per unit 
95% Confidence 
intervals 
SBP 
change 
per unit 
95% Confidence 
intervals 
UVA (W/m2) 
-0.0032 (-0.0037 to -0.0027) -0.0023 (-0.0029 to -0.0016) 
MALE 
-3.6899 (-3.9412 to -3.4387) -1.7891 (-2.0942 to -1.4841) 
AGE (years) 
-0.1913 (-0.2001 to -0.1825) -0.0735 (-0.0846 to -0.0624) 
EPO DOSE 
(U/dialysis)  
0.2474 (0.2330 to 0.2618) 0.4322 (0.4115 to 0.4528) 
ALBUMIN (g/dL) 
4.4834 (4.3117 to 4.6551) 4.1338 (3.9217 to 4.3459) 
INTERDIALYTIC 
WEIGHT GAIN (kg) 
-0.8487 (-0.9205 to -0.7768) -0.8207 (-0.9130 to -0.7285) 
SERUM SODIUM 
(mEq/L) 
0.1576 (0.1436 to 0.1717) 0.2104 (0.1963 to 0.2245) 
BMI (kg/m2) 
0.2410 (0.2197 to 0.2623) 0.2788 (0.2508 to 0.3068) 
SERUM POTASSIUM 
(mEq/L) 
0.3763 (0.2761 to 0.4765) 0.2340 (0.1594 to 0.3087) 
HYPERTENSION 
5.3134 (5.0336 to 5.5931) 3.7728 (3.3570 to 4.1886) 
HGB (g/dL) 
1.1998 (1.1478 to 1.2519) 0.5527 (0.4999 to 0.6055) 
CATHETER AS 
VASCULAR ACCESS 
0.4515 (0.2582 to 0.6448) 0.6925 (0.4372 to 0.9477) 
TIME (months) 
-0.0470 (-0.0561 to -0.0379) -0.0716 (-0.0828 to -0.0603) 
TEMPERATURE 
(Celsius) 
-0.0813 (-0.0899 to -0.0727) -0.0737 (-0.0847 to -0.0626) 
UVB (W/m2) 
-0.0563 (-0.0648 to -0.0478) -0.0417 (-0.0526 to -0.0308) 
MALE 
-3.6862 (-3.9383 to -3.4340) -1.7929 (-2.0984 to -1.4874) 
AGE (years) 
-0.1913 (-0.2002 to -0.1825) -0.0735 (-0.0846 to -0.0625) 
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EPO DOSE 
(U/dialysis) 
0.2472 (0.2328 to 0.2615) 0.4320 (0.4114 to 0.4527) 
ALBUMIN (g/dL) 
4.4852 (4.3142 to 4.6561) 4.1349 (3.9227 to 4.3472) 
INTERDIALYTIC 
WEIGHT GAIN (kg) 
-0.8490 (-0.9208 to -0.7773) -0.8209 (-0.9132 to -0.7286) 
SERUM SODIUM 
(mEq/L) 
0.1573 (0.1444 to 0.1703) 0.2104 (0.1964 to 0.2245) 
BMI (kg/m2) 
0.2411 (0.2198 to 0.2624) 0.2790 (0.2510 to 0.3070) 
SERUM POTASSIUM 
(mEq/L) 
0.3841 (0.3037 to 0.4644) 0.2339 (0.1592 to 0.3086) 
HYPERTENSION 
5.3053 (5.0242 to 5.5865) 3.7771 (3.3623 to 4.1919) 
HGB (g/dL) 
1.1954 (1.1475 to 1.2433) 0.5522 (0.4993 to 0.6051) 
CATHETER AS 
VASCULAR ACCESS 
0.4522 (0.2587 to 0.6457) 0.6936 (0.4382 to 0.9490) 
TIME (months) 
-0.0476 (-0.0566 to -0.0385) -0.0720 (-0.0832 to -0.0608) 
TEMPERATURE 
(Celsius) 
-0.0792 (-0.0878 to -0.0707) -0.0704 (-0.0815 to -0.0594) 
 
The dose of erythropoietin (EPO DOSE) was transformed by raising it to the power of ¼. 
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Table S10. Estimated coefficients from Model 2 with an extra term of AGE^2, stratified by 
wavelength band and race.  
 
White Black 
Covariates 
SBP 
change 
per unit 
95% Confidence 
intervals 
SBP 
change 
per unit 
95% Confidence 
intervals 
UVA (W/m2) -0.0076 (-0.008 to -0.0073) -0.0063 (-0.0067 to -0.0059) 
MALE -3.8402 (-4.1005 to -3.5799) -1.9283 (-2.2605 to -1.596) 
AGE (years) -0.2079 (-0.2173 to -0.1984) -0.1243 (-0.138 to -0.1106) 
AGE2 (years2) -0.0045 (-0.005 to -0.0041) -0.005 (-0.0056 to -0.0045) 
EPO DOSE (U/dialysis) 0.2464 (0.2314 to 0.2614) 0.4279 (0.4063 to 0.4496) 
ALBUMIN (g/dL) 4.5825 (4.4072 to 4.7579) 4.303 (4.0771 to 4.5289) 
INTERDIALYTIC 
WEIGHT GAIN (kg) -0.8901 (-0.9637 to -0.8166) -0.8074 (-0.9047 to -0.71) 
SERUM SODIUM 
(mEq/L) 0.1647 (0.1521 to 0.1773) 0.2261 (0.2105 to 0.2418) 
BMI (kg/m2) 0.2204 (0.198 to 0.2428) 0.2781 (0.2504 to 0.3057) 
SERUM POTASSIUM 
(mEq/L) 0.3918 (0.3289 to 0.4547) 0.2519 (0.1677 to 0.3361) 
HYPERTENSION 5.2616 (4.9503 to 5.5729) 3.433 (3.0005 to 3.8655) 
HGB (g/dL) 1.1452 (1.0991 to 1.1912) 0.5172 (0.4611 to 0.5732) 
CATHETER AS 
VASCULAR ACCESS 0.5248 (0.3254 to 0.7242) 0.6851 (0.4213 to 0.9488) 
TIME (months) -0.0624 (-0.0714 to -0.0534) -0.0781 (-0.0898 to -0.0663) 
UVB (W/m2) -0.1292 (-0.1349 to -0.1235) -0.1051 (-0.1118 to -0.0983) 
MALE -3.8414 (-4.1015 to -3.5813) -1.9302 (-2.2625 to -1.5978) 
AGE (years) -0.2079 (-0.2174 to -0.1985) -0.1243 (-0.138 to -0.1106) 
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AGE2 (years2) -0.0046 (-0.0122 to 0.003) -0.0048 (-0.0155 to 0.0059) 
EPO DOSE (U/dialysis) 0.2465 (0.2315 to 0.2616) 0.4284 (0.4068 to 0.45) 
ALBUMIN (g/dL) 4.5827 (4.4073 to 4.758) 4.3029 (4.077 to 4.5287) 
INTERDIALYTIC 
WEIGHT GAIN (kg) -0.8922 (-0.9658 to -0.8187) -0.8088 (-0.9061 to -0.7114) 
SERUM SODIUM 
(mEq/L) 0.1644 (0.1518 to 0.177) 0.2256 (0.21 to 0.2412) 
BMI (kg/m2) 0.2204 (0.1981 to 0.2428) 0.2782 (0.2506 to 0.3059) 
SERUM POTASSIUM 
(mEq/L) 0.3925 (0.3296 to 0.4554) 0.2524 (0.1682 to 0.3365) 
HYPERTENSION 5.2621 (4.951 to 5.5733) 3.4356 (3.0031 to 3.868) 
HGB (g/dL) 1.146 (1.0999 to 1.1921) 0.5184 (0.4623 to 0.5744) 
CATHETER AS 
VASCULAR ACCESS 0.5238 (0.3243 to 0.7232) 0.6835 (0.4197 to 0.9472) 
TIME (months) -0.0619 (-0.0709 to -0.0529) -0.0778 (-0.0896 to -0.0661) 
 
The dose of erythropoietin (EPO DOSE) was transformed by raising it to the power of ¼. 
 
  
D
ow
nloaded from
 http://ahajournals.org by on March 6, 2020
Table S11. Estimated coefficients from Model 3 with an extra term of AGE^2, stratified by 
wavelength band and race.  
 
White Black 
Covariates 
SBP 
change 
per unit 
95% Confidence 
intervals 
SBP 
change per 
unit 
95% Confidence 
intervals 
UVA (W/m2) -0.0031 (-0.0037 to -0.0026) -0.0021 (-0.0028 to -0.0013) 
MALE -3.84 (-4.1012 to -3.5789) -1.9035 (-2.2361 to -1.5708) 
AGE (years) -0.2087 (-0.2181 to -0.1993) -0.124 (-0.1377 to -0.1103) 
AGE2 (years2) -0.0046 (-0.0051 to -0.0041) -0.005 (-0.0056 to -0.0045) 
EPO DOSE (U/dialysis) 0.2489 (0.2338 to 0.264) 0.4326 (0.4109 to 0.4544) 
ALBUMIN (g/dL) 4.536 (4.3604 to 4.7117) 4.2458 (4.0193 to 4.4722) 
INTERDIALYTIC 
WEIGHT GAIN (kg) -0.8984 (-0.972 to -0.8249) -0.8213 (-0.9188 to -0.7238) 
SERUM SODIUM 
(mEq/L) 0.1565 (0.144 to 0.1691) 0.2197 (0.2041 to 0.2353) 
BMI (kg/m2) 0.2194 (0.1969 to 0.2419) 0.2756 (0.2478 to 0.3033) 
SERUM POTASSIUM 
(mEq/L) 0.3863 (0.3236 to 0.4491) 0.2398 (0.1554 to 0.3241) 
HYPERTENSION 5.259 (4.947 to 5.5711) 3.4428 (3.0094 to 3.8762) 
HGB (g/dL) 1.1637 (1.1177 to 1.2097) 0.5419 (0.4858 to 0.5979) 
CATHETER AS 
VASCULAR ACCESS 0.5173 (0.3177 to 0.7169) 0.6737 (0.409 to 0.9384) 
TIME (months) -0.0517 (-0.0609 to -0.0425) -0.0712 (-0.0832 to -0.0592) 
TEMPERATURE 
(Celsius) -0.0849 (-0.0939 to -0.0759) -0.0791 (-0.0914 to -0.0667) 
UVB (W/m2) -0.0556 (-0.0646 to -0.0466) -0.0384 (-0.0509 to -0.0259) 
MALE -3.8425 (-4.1034 to -3.5816) -1.9065 (-2.2391 to -1.5738) 
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AGE (years) -0.2087 (-0.2181 to -0.1993) -0.124 (-0.1376 to -0.1103) 
AGE2 (years2) -0.0046 (-0.0051 to -0.0041) -0.005 (-0.0056 to -0.0045) 
EPO DOSE (U/dialysis) 0.2488 (0.2338 to 0.2639) 0.4327 (0.411 to 0.4544) 
ALBUMIN (g/dL) 4.5366 (4.361 to 4.7123) 4.2482 (4.0218 to 4.4746) 
INTERDIALYTIC 
WEIGHT GAIN (kg) -0.8994 (-0.9729 to -0.8258) -0.8215 (-0.919 to -0.724) 
SERUM SODIUM 
(mEq/L) 0.1565 (0.144 to 0.1691) 0.2197 (0.2041 to 0.2353) 
BMI (kg/m2) 0.2194 (0.1969 to 0.2419) 0.2758 (0.2481 to 0.3035) 
SERUM POTASSIUM 
(mEq/L) 0.3868 (0.3241 to 0.4495) 0.2406 (0.1563 to 0.325) 
HYPERTENSION 5.2589 (4.9469 to 5.5708) 3.4449 (3.0116 to 3.8783) 
HGB (g/dL) 1.1637 (1.1177 to 1.2098) 0.5416 (0.4855 to 0.5977) 
CATHETER AS 
VASCULAR ACCESS 0.5167 (0.317 to 0.7163) 0.673 (0.4082 to 0.9377) 
TIME (months) -0.0519 (-0.0611 to -0.0428) -0.0715 (-0.0835 to -0.0595) 
TEMPERATURE 
(Celsius) -0.0828 (-0.0918 to -0.0739) -0.0756 (-0.0879 to -0.0632) 
 
The dose of erythropoietin (EPO DOSE) was transformed by raising it to the power of ¼. 
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Table S12. Relationship between systolic blood pressure (SBP) and standardized ultraviolet light 
as well as standardized temperature, stratified by race and wavelength band.  
  
White Black 
Model UV band 
SBP change 
per unit UV  
95% Confidence 
intervals 
SBP change 
per unit UV 
95% Confidence 
intervals 
1 
UVA -0.93 (-0.96 to -0.90) -0.76 (-0.80 to -0.72) 
UVB -0.94 (-0.97 to -0.91) -0.74 (-0.80 to -0.72) 
2 
UVA -0.90 (-0.94 to -0.86) -0.74 (-0.78 to -0.70) 
     UVB -0.91 (-0.95 to -0.87) -0.75 (-0.78 to -0.71) 
3 
UVA -0.38 (-0.44 to -0.32) -0.27 (-0.34 to -0.20) 
Temp -0.73 (-0.81 to -0.65) -0.67 (-0.77 to -0.56) 
UVB -0.40 (-0.46 to -0.34) -0.30 (-0.37 to -0.23) 
Temp -0.71 (-0.79 to -0.63) -0.64 (-0.74 to -0.53) 
 
A standardized variable was calculated by subtracting mean and dividing by standard deviation of the 
original variable. 
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Table S13. Relationship between systolic blood pressure (SBP) and ultraviolet light, stratified by 
race and temperature.  
  
White Black 
Temp [ºC] UV band 
SBP change 
per unit UV  
95% Confidence 
intervals 
SBP change 
per unit UV 
95% Confidence 
intervals 
<9.4 
UVA -0.51 (-0.61 to -0.42) -0.03 (-0.16 to -0.09) 
UVB -10.64 (-12.47 to -8.81) -1.39 (-3.71 to -0.92) 
9.4-17 
UVA -1.04 (-1.11 to -0.96) -0.87 (-0.97 to -0.77) 
UVB -16.94 (-18.28 to -15.60) -14.40 (-16.08 to -12.72) 
17-23.2 
UVA -0.97 (-1.06 to -0.89) -0.61 (-0.72 to -0.50) 
UVB -14.28 (-15.65 to -12.90) -8.61 (-10.34 to -6.87) 
>23.2 
UVA -2.21 (-2.35 to -2.08) -0.34 (-0.52 to -0.16) 
UVB -29.19 (-31.29 to -27.09) -2.02 (-4.83 to 0.80) 
Combined 
UVA        -1.18 (-1.74 to -0.63) -0.47 (-0.84 to -0.09) 
UVB -17.73 (-24.15 to -11.32) -6.67 (-12.72 to -0.61) 
 
A linear model with all covariates in Model 3 is fitted to each stratum. 
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Figure S1. Geographical Location of Dialysis Facilities at which Blood Pressure Data were 
collected (panel A) and spatial distribution of patient numbers by State (panel B). 
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Figure S2. Average UVA (W.m-2) in the four seasons. 
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Figure S3. Average UVB (W.m-2) in the four seasons. 
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Figure S4. Average temperature (degree Celsius) in the four seasons. 
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